India's pharmaceutical industry has moved up the value chain. Finished medicines — formulations and biologicals — now account for 75% of $31 billion in exports. Vaccine shipments alone: $1.55 billion.
487 pharmaceutical product lines across five categories. Medicines dominate — but APIs, vaccines, surgical supplies, and traditional formulations round out a broad portfolio trusted by health systems worldwide.
India exports $4.8 billion in active pharmaceutical ingredients and bulk drugs each year — the raw materials that become the world’s finished medicines. A decade ago that figure was $2.7 billion. Formulations have grown faster (India is moving up the value chain), but APIs remain foundational: you cannot make the medicine without the ingredient.
Named categories where customs codes resolve to specific compound classes:
61% of India’s API exports fall under generic customs headings (“bulk drugs and drug intermediates”) that do not name the specific compound. This is not unique to India — customs systems worldwide do not finely track API trade, which is part of why pharmaceutical supply chains are opaque. Governments seeking to understand API dependency must look beyond trade statistics.
APIs flow to three types of buyer: large-market importers (US, Brazil) that buy both finished drugs and raw ingredients; manufacturing hubs (Netherlands, Belgium, Ireland, Switzerland) that import Indian APIs to produce medicines for their own markets; and emerging manufacturers (Bangladesh, Egypt, Turkey) building domestic pharmaceutical capacity from imported Indian ingredients.
India makes the raw ingredients the world’s medicines are built from. When a hospital needs an antibiotic, the active ingredient likely started in India.
The COVID-19 pandemic exposed concentration risk in API supply chains. India is the dominant global supplier of key intermediates — antibiotics, hormones, vitamins — and supply-chain diversification is now a policy priority in both the United States and the European Union. Recent legislation in both jurisdictions has targeted pharmaceutical supply chain security and domestic API manufacturing capacity. The opacity of API trade data — two-thirds classified under catch-all customs codes — is itself part of the policy problem: you cannot secure a supply chain you cannot see.
Source: DGCIS India (pharma exports, 205 API product codes from the DGCIS pharmaceutical basket, CY 2014–2025). All values in US dollars.